An orexin agonist restores wakefulness in narcolepsy type 1

Design

two phase 3, randomised, placebo-controlled trials over 12 weeks (First Light and Radiant Light)

Population

273 participants aged 16 to 70 years with narcolepsy type 1 (168 in First Light, 105 in Radiant Light)

Primary outcome

change from baseline to week 12 in mean sleep latency on the Maintenance of Wakefulness Test

Effect

sleep latency +14.3 to +19.8 minutes vs -0.4 to -0.8 with placebo (adjusted P<0.001); Epworth -9.7 to -11.8 vs -1.5 to -1.7; weekly cataplexy down a median 79.0-88.8% vs 27.7-39.1%

Narcolepsy type 1 is caused by loss of orexin-producing neurons, and every treatment until now has worked around that deficit with stimulants and sodium oxybate rather than replacing the missing signal. Oveporexton is an oral orexin receptor 2-selective agonist, and these are its two phase 3 trials: First Light randomised 168 participants aged 16 to 70 in a 3:3:2 ratio to 1 mg twice daily, 2 mg twice daily or placebo, and Radiant Light randomised 105 in a 2:1 ratio to 2 mg twice daily or placebo, both over 12 weeks.

The primary endpoint was mean sleep latency on the Maintenance of Wakefulness Test, which measures how long someone can stay awake in conditions designed to send them to sleep; the scale runs to 40 minutes and 20 or above is normal. Sleep latency rose by 14.3 to 19.8 minutes across the active groups and fell by 0.4 to 0.8 minutes on placebo. Epworth Sleepiness Scale scores fell by 9.7 to 11.8 points against 1.5 to 1.7 on placebo, and weekly cataplexy attacks fell by a median 79.0% to 88.8% against 27.7% to 39.1%.

Effect sizes of this magnitude are unusual in any therapeutic area, and they matter for a condition where existing treatments improve sleepiness without approaching normal wakefulness. Replacing the deficient signal appears to do something that stimulating alertness does not.

Set against that, adverse events occurred in 86% to 89% of participants on the drug against 43% to 54% on placebo, and the two commonest, increased urinary frequency and transient insomnia, affected a majority of those treated. Both are mechanistically plausible for an orexin agonist. The trials ran 12 weeks, so durability and longer-term safety are unknown, and this report establishes efficacy rather than any regulatory position: availability in India is not something these results address.

• Note that the treatment target here is the orexin deficit itself, not general alertness
• Expect urinary frequency and transient insomnia to dominate the side-effect conversation if this class reaches practice
• Judge narcolepsy treatment by objective wakefulness and cataplexy rate, not by the patient saying they feel better
• Remember these are 12-week trials: nothing here speaks to durability, tolerance or long-term safety
• Do not tell patients this is available; the trials establish efficacy and say nothing about approval or supply here

The statistics, in plain English

A rise of 14 to 20 minutes on a 40-minute scale, from a low baseline, moves patients from failing the test to close to the normal range, which is why this counts as a large effect rather than a statistically detectable one. Placebo changed the score by under a minute, so the comparison is not doing much work: the drug effect is the result. The Epworth fall of around 10 points is roughly the distance between severe pathological sleepiness and the normal range. The side-effect figures deserve equal weight: an 86% to 89% adverse event rate against 43% to 54% on placebo means most patients felt something, and with 12 weeks of data there is no information on whether those effects settle.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.